New breast cancer research highlighting the value of Agendia’s MammaPrint® and BluePrint® genomic tests will be presented in 10 scientific posters at the upcoming 2015 San Antonio Breast Cancer Symposium (SABCS).

Four of the posters will provide new findings from the NBRST trial, which encompasses results from more than 1,000 patients. The trial has produced results that consistently underscore the unique ability of functional molecular subtyping, compared to standard clinicopathologic classification alone, to better predict those patients who will respond to chemotherapy and/or targeted therapy.

Agendia will also offer a satellite symposium on “The Significance of Prospective Randomized Trials in Genomic Testing Validation and the Advancement of Precision Medicine,” featuring two of the world’s leading scientists in genomic medicine. The symposium will be led by guest speakers Emiel Rutgers, F.R.C.S., M.D., Ph.D., head of the Department of Surgery at the Netherlands Cancer Institute, and Laura van ’t Veer, Ph.D., Leader, Breast Oncology Program and Director, Applied Genomics at University of California, San Francisco. They will discuss the MINDACT trial design and the significance of prospective randomized trials in genomic testing validation. The symposium will be held Wednesday, Dec. 9 at 2 p.m. in the Exhibit Hall’s Product Theater.

On Thursday, Dec.10, Agendia will host a dinner presentation on Molecular Subtypes. Peter Beitsch, M.D. and Pat Whitworth, M.D. of Targeted Medical Education will discuss functional molecular subtypes and emerging research in the management of early stage breast cancer. The dinner will take place at Bohanans Prime Steaks and Seafood at 219 East Houston Street, 2nd Floor, in San Antonio. A welcome reception starts at 6:30 P.M. with the presentation beginning at 7:00 p.m.

For more information about both of these events, please inquire at the Agendia conference Booth #518.

The Agendia-related poster presentations at SABCS and their authors are:

Wednesday, December 9

Poster P1-14-05: Three distinct HER2 subtypes identified by BluePrint 80-gene functional subtyping predict treatment-specific response in the prospective neo-adjuvant NBRST registry (NBRST)

Authors: Pat Whitworth, Peter Beitsch, Paul Baron, Jennifer Beatty, James V Pellicane, Mary K. Murray, Carrie L Dul, Angela M Mislowsky, Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots, Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Michael C Rotkis

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

P1-14-10: Phase II trial of neoadjuvant chemotherapy (NCT) with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer (TNBC) (Somlo)

Authors: Somlo G, Chung S, Frankel P, Hurria A, Koehler S, Kruper L, Mortimer JE, Paz B, Robinson K, Taylor L, Vito C, Waisman J, Yeon C, Yim J, Yuan Y, Tong T

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Thursday, December 10

Poster P3-07-67: Chemosensitivity and endocrine sensitivity predicted by MammaPrint and BluePrint in clinical Luminal patients in the prospective NBRST study (NBRST)

Authors: James V Pellicane, Pat Whitworth, Peter Beitsch, Paul Baron, Jennifer Beatty, Mary Murray, Carrie L Dul, Angela M Mislowsky, Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots, Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Michael C Rotkis

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Poster OT2-03-01: Measuring the Impact of MammaPrint on treatment in Breast Cancer Patients: A Prospective Registry (IMPaCt)

Authors: Lowell L. Hart, Sarah Untch, Lisette Stork-Sloots

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Friday, December 11

Poster P4-14-10: Pertuzumab overcomes chemotherapy/trastuzumab resistance in ER+/Her2+ tumors classified as Luminal functional subtype by the 80-gene BluePrint assay in the prospective Neo-adjuvant Breast Registry Symphony Trial (NBRST)

Authors: Peter Beitsch, Pat Whitworth, Paul Baron, Jennifer Beatty, James V Pellicane, Mary K. Murray, Carrie L Dul, Angela M Mislowsky, Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots, Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Michael C Rotkis

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P4-14-29: One-third of HER2 positive patients have 80-gene Luminal subtype that is resistant to Chemo-trastuzumab but sensitive to Chemo-trastuzumab-pertuzumab: critical implications for the adjuvant setting from the NBRST neoadjuvant registry (NBRST)

Authors: Peter Beitsch, Pat Whitworth, Paul Baron, Jennifer Beatty, James V Pellicane, Mary K. Murray, Carrie L Dul, Angela M Mislowsky, Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots, Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Michael C Rotkis

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P5-13-07: An Investigator-Initiated Registry Trial of Simple Oral Therapy for Low Risk Breast Cancer (FHCRC)

Authors: VK Gadi, Courtney Preusse, Kristine Calhoun, Janice Kim, Hannah Linden, Mara Rendi, Ruth Etzioni, Ted Gooley, Gary Lyman, Lisette Stork, Vastiaan van der Baan, Neil Barth, Habib Rahbar

Exhibit Halls A-B, Time: 5:00 p.m. – 7:00 p.m.

Saturday, December 12

Poster P6-05-07: Improving personalized management of primary breast cancer: Mammaprint® Risk stratification and Blueprint® molecular subtyping

Authors: Lekha Mikkilineni, Laura K. Austin, Kimberly Limentani, Rebecca J. Jaslow, Tiffany P. Avery, Juan Palazzo, and Massimo Cristofanilli

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles (AFTER)

Authors: Sabine C. Linn, Tesa M. Severson, Ekaterina Nevedomskaya, Justine Peeters, Annelot van Rossum, Thomas Kuilman, Oscar Krijgsman, Ines Goossens, Annuska Glas, Rutger Koornstra, Daniel Peeper, Jelle Wesseling, Iris M. Simon, Lodewyk Wessels, Wilbert Zwart

Exhibit Halls A-B, Time: 7:30 a.m. – 9:00 a.m.

Poster P6-09-01: Identification of tumors with an indolent disease course: MammaPrint Ultralow signature validation in a retrospective analysis of a Swedish randomized tamoxifen trial (STO)

Authors: Laura J Esserman, Carlie K Thompson, Christina Yau, Laura J van ‘t Veer, Alexander D Borowsky, Nicholas P Tobin, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Christopher C Benz, Linda S Lindström

Exhibit Halls A-B, Time 7:30 a.m. – 9:00 a.m.

The 70-gene MammaPrint test, an FDA-cleared FFPE, second-generation breast cancer recurrence assay, provides definitive High Risk or Low Risk information about breast cancer recurrence, with no “intermediate” results. Agendia’s companion BluePrint test is the only widely available assay that provides functional molecular subtypes. It delivers enhanced information about which patients may or may not respond to neoadjuvant (preoperative) therapy and also assists physicians and their patients in determining the best course for therapy. The Agendia tests have substantial insurance coverage encompassing an estimated 200 million lives, including coverage by Medicare and regional and national insurers. To learn more about the tests, SABCS attendees can visit Booth #518.

SABCS 2015 will be held at the Henry Gonzales Conference Center in San Antonio, Texas, USA, Dec. 8-12, 2015.

Resources for further reference

* MammaPrint/Blueprint Predict Response to Targeted Treatment Regimens press release

* NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis press release

* Independent comparison validates molecular subtyping (includes video)

* RASTER prospective study concludes some can safely forego chemotherapy press release

About Agendia

Agendia is a privately owned, leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome.

This includes the MammaPrint test, which is the only FDA-cleared test for women of all ages and which is not limited by estrogen receptor status. Agendia's suite of tests includes BluePrint, which in combination with MammaPrint provides the only commercially available way to predict response to current breast cancer chemotherapy and targeted therapy regimens. In addition to MammaPrint and BluePrint, which is a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology, Agendia also offers TargetPrint®, an ER/PR/HER2 expression assay.

Agendia’s tests help physicians assess a breast cancer patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the I-SPY 2 and the MINDACT trials. For more information, visit www.agendia.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151207005294/en/